Search Results - "STEFFEL, J."

Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial by Steffel, J, Giugliano, R P, Braunwald, E, Murphy, S A, Atar, D, Heidbuchel, H, Camm, A J, Antman, E M, Ruff, C T

“…In the ENGAGE AF-TIMI 48 trial, the higher-dose edoxaban (HDE) regimen had a similar incidence of ischaemic stroke compared with warfarin, whereas a higher…”
Get full text

Multiple clinical profiles of families with the short QT syndrome by Akdis, D, Saguner, A M, Medeiros-Domingo, A, Schaller, A, Balmer, C, Steffel, J, Brunckhorst, C, Duru, F

“…Short QT syndrome (SQTS) is a rare cardiac channelopathy characterized by a shortened corrected QT (QTc)-interval that can lead to ventricular arrhythmias and…”
Get full text

The effects of continuous positive airway pressure therapy withdrawal on cardiac repolarization: data from a randomized controlled trial by ROSSI, Valentina A, STOEWHAS, Anne-Christin, CAMEN, Giovanni, STEFFEL, Jan, BLOCH, Konrad E, STRADLING, John R, KOHLER, Malcolm

“…The preliminary evidence supports an association between obstructive sleep apnoea (OSA), disturbed cardiac repolarization, and consequent cardiac dysrhythmias…”
Get full text

Electrocardiographic changes in early recognition of Fabry disease by Namdar, Mehdi, Steffel, Jan, Vidovic, Mile, Brunckhorst, Corinna B, Holzmeister, Johannes, Lüscher, Thomas F, Jenni, Rolf, Duru, Firat

“…Fabry disease (FD) is an inherited X-chromosomal lysosomal storage disease resulting in intracellular storage of globotriaosylceramide. Cardiac involvement is…”
Get more information

Individualized antithrombotic therapy by Lüscher, T F, Steffel, J

“…Clot formation in the circulation is a physiological mechanism preventing bleeding at sites of loss of vascular integrity. Clot formation may also occur…”
Get more information

Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents by Camici, Giovanni G., Steffel, Jan, Amanovic, Ilijana, Breitenstein, Alexander, Baldinger, Janette, Keller, Stephan, Lüscher, Thomas F., Tanner, Felix C.

“…Aims Drug-eluting stents (DES) may be associated with an increased risk for stent thrombosis when compared with bare-metal stents. In endothelial cells,…”
Get full text

Vitamin K antagonists. Ready to be replaced? by Steffel, J, Luscher, T F

“…For the last decades, anticoagulation for stroke prevention in atrial fibrillation (AF) as well as for the prophylaxis and long-term treatment of venous…”
Get more information

The year in cardiology 2017: arrhythmias and cardiac devices by Linde, Cecilia, Steffel, Jan

Get full text

Histamine differentially interacts with tumor necrosis factor‐α and thrombin in endothelial tissue factor induction: the role of c‐Jun NH2‐terminal kinase by STEFFEL, J., ARNET, C., AKHMEDOV, A., ISELI, S. M., LÜSCHER, T. F., TANNER, F. C.

“…Background: Histamine plays an important role in vascular disease. Tissue factor (TF) expression is induced in vascular inflammation and acute coronary…”
Get full text

Single center experience with a novel short rotating dilator sheath in transvenous lead extraction by Hofer, D, Frei, C, Steffel, J, Breitenstein, A

“…Abstract Funding Acknowledgements Type of funding sources: None. Background Transvenous lead extraction has become a frequent procedure in the context of…”
Get full text

Systematic screening for right-to-left shunt prior to lead extraction by Breitenstein, A, Hofer, D, Starck, CH, Steffel, J

“…Abstract Funding Acknowledgements Type of funding sources: None. Background Transvenous lead extraction has become a relevant treatment option in patients with…”
Get full text

Impact of body weight and body mass index on clinical outcomes of edoxaban therapy in atrial fibrillation patients included in the ETNA-AF-Global registry by Boriani, G, Souza, J, Steffel, J, Koretsune, Y, Chao, T F, Weiss, T, Zaremba-Pechman, L, Borrow, A P, Unverdorben, M, De Caterina, R

“…Abstract Background In atrial fibrillation (AF) patients (pts) receiving non-vitamin K antagonist oral anticoagulant therapy, extreme body weights, both…”
Get full text

Edoxaban for stroke prevention in routine practice patients with atrial fibrillation with and without atherosclerotic disease: a post-hoc sub-study of ETNA-AF-Europe by De Vries, T A C, De Groot, J R, Hemels, M E W, Komen, J J, Steffel, J, Weiss, T, De Asmundis, C, Kirchhof, P, De Caterina, R

“…Abstract Background Patients with atrial fibrillation (AF) and concomitant coronary and peripheral artery disease (CAD and/or PAD) have an increased risk of…”
Get full text

Electrocardiographic predictors of atrial mechanical sensing in patients with leadless VDD pacemakers by Hofer, D, Perucchini, F, Zehetleitner, S, Saguner, A, Haeberlin, A, Steffel, J, Breitenstein, A

“…Abstract Funding Acknowledgements Type of funding sources: None. Background Leadless pacemakers (LP) capable of VDD function are a cornerstone of modern…”
Get full text

3D atrial strain for prediction of atrial fibrillation recurrence by Krizanovic-Grgic, I, Anwer, S, Steffel, J, Hofer, D, Saguner, A M, Spengler, C M, Breitenstein, A, Tanner, F C

“…Abstract Introduction Atrial fibrillation (AF) is one of the most common supraventricular arrhythmias. Treatment options apart from medication include…”
Get full text

Is there a role for half-dose anticoagulation in atrial fibrillation? Randomized comparison of 2 doses of edoxaban in 14,014 patients in ENGAGE AF-TIMI 48 by Steffel, J, Ruff, C.T, Braunwald, E, Park, J.G, Murphy, S, Antman, E.M, Giugliano, R.P

“…Abstract Background In the phase 3 RCT ENGAGE AF-TIMI 48, both the higher-dose (HDER/edoxaban 60/30mg) and lower-dose edoxaban regimen (LDER/edoxaban 30/15mg)…”
Get full text

Improved prediction of cardiac, limb and bleeding events in patients with coronary and peripheral arterial disease using machine learning models and artificial intelligence by Steffel, J, Kloss, S, Roohi Sefidmazgi, N, Chevreux, B, Fox, K.A.A

“…Abstract Background Coronary artery disease (CAD) and peripheral arterial disease (PAD) represent a significant burden in patients with cardiovascular disease…”
Get full text

Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: A joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology by Mullens, Wilfried, Auricchio, Angelo, Martens, Pieter, Witte, Klaus, Cowie, Martin R, Delgado, Victoria, Dickstein, Kenneth, Linde, Cecilia, Vernooy, Kevin, Leyva, Francisco, Bauersachs, Johann, Israel, Carsten W, Lund, Lars H, Donal, Erwan, Boriani, Giuseppe, Jaarsma, Tiny, Berruezo, Antonio, Traykov, Vassil, Yousef, Zaheer, Kalarus, Zbigniew, Cosedis Nielsen, Jens, Steffel, Jan, Vardas, Panos, Coats, Andrew, Seferovic, Petar, Edvardsen, Thor, Heidbuchel, Hein, Ruschitzka, Frank, Leclercq, Christophe

“…Cardiac resynchronization therapy (CRT) is one of the most effective therapies for heart failure with reduced ejection fraction and leads to improved quality…”
Get full text

Left femoral venous access for leadless pacemaker implantation: patient characteristics and outcomes by Jelisejevas, J, Breitenstein, A, Hofer, D, Winnik, S, Steffel, J, Saguner, A

“…Abstract Funding Acknowledgements Type of funding sources: None. Background Leadless pacing has become an alternative approach for patients requiring a…”
Get full text

Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year follow-up of more than 13,000 patients from the ETNA-AF-Europe study by Kirchhof, P, Bakhai, A, De Groot, J R, Deharo, J C, Levy, P, Lopez-De-Sa, E, Monteiro, P, Steffel, J, Waltenberger, J, Fronk, E M, Lamparter, M, Laeis, P, Smolnik, R, De Caterina, R

“…Abstract Background Direct, non-vitamin K antagonist oral anticoagulants (DOACs/NOACs) have become the first-choice therapy for stroke prevention in patients…”
Get full text